N-(1H-Benzimidazol-2-ylmethyl)-N-[(8S)-5,6,7,8-tetrahydro-8-quinolinyl]-1,4-butanediamine is a potent CXCR4 inhibitor that inhibits X4 HIV-1 replication and the gp120/CXCR4 interaction. It also has therapeutic potential for developing treatments for B-RAF wild-type and mutated melanomas.